Results - Announcements
Marksans Pharma Ltd share price softened by 4.43% to Rs 301.15 after the company's net profit eased 9.96% to Rs 143.53 crore, while revenue from operations gained 11.82% to Rs 940.17 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.82 lakh crore, easing 5.14%. It has marginally improved by 2.03% over last one week and moved up slightly by 1.77% in last one month while the market capitalization of Marksans Pharma Ltd has eased by 4.43% and 9.99% in the same period respectively.
Profit before tax (PBT) of Marksans Pharma Ltd stood at Rs 193.5 crore in Q3 FY26, surging by 45.13% year-on-year, and declining 6.33% quarter-on-quarter. EBITDA came in at Rs 196 crore, expanding by 59.55% YoY and gaining 4.54% sequentially.
Total expenses advancing by 16.14% to Rs 757.99 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 231.49 crore, growing marginally by 4.90% YoY, while employee benefits expense was at Rs 122.32 crore, improving by 7.03% YoY.
For the TTM ended FY26, revenue from operations improved 12.51% to Rs 2950.94 crore, while net profit saw a marginal increase of 9.79% to Rs 420.06 crore, compared to previous TTM. EBITDA soared by 48060% to Rs 518.25 crore, and PBT expanded by 11.23% to Rs 560.56 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 458.13 crore in FY26, as against Rs 206.66 crore in FY25.
Marksans Pharma Ltd surged by 61.26% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 7.38% during the same period.